Business Context and Reporting Period
This Form 8-K was filed by ArTara Therapeutics, Inc. (formerly Proteon Therapeutics, Inc.) on March 23, 2020, reporting events occurring on March 18, 2020. The Company completed a merger and reorganization on January 9, 2020, with privately-held ArTara Therapeutics, Inc., resulting in a name change from Proteon Therapeutics, Inc. to ArTara Therapeutics, Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes regarding the independent registered public accounting firm.
Material Changes
- Resignation of Auditor: The Audit Committee confirmed the resignation of Ernst & Young LLP as the independent registered public accounting firm, effective March 23, 2020.
- Appointment of New Auditor: The Audit Committee approved the engagement of Marcum LLP as the independent registered public accounting firm for the year ending December 31, 2020.
- Audit History: Reports by Ernst & Young LLP for the years ended December 31, 2019, and 2018, did not contain adverse opinions, disclaimers, or qualifications. There were no disagreements or reportable events during these periods.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies related to financial operations were disclosed in this document. The transition of auditors was conducted without reported disagreements on accounting principles or auditing scope.
Investor Verification Checklist
- Verify the effective date of the auditor transition (March 23, 2020) and the rationale for the change.
- Confirm the absence of any undisclosed disagreements between the Company and Ernst & Young LLP prior to resignation.
- Review the letter from Ernst & Young LLP (Exhibit 16.1) to ensure they agree with the statements made in the filing.
- Monitor future filings for the first financial statements audited by Marcum LLP.